• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Precision BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    5/15/25 8:00:20 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DTIL alert in real time by email
    8-K
    0001357874false00013578742025-05-152025-05-15

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 15, 2025

     

     

    Precision BioSciences, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38841

    20-4206017

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    302 East Pettigrew St.

    Suite A-100

     

    Durham, North Carolina

     

    27701

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 919 314-5512

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.000005 per share

     

    DTIL

     

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


     

     

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 15, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 7.01. Regulation FD Disclosure.

    The Company has updated its corporate deck, which is available in the “Investors” portion of the Company’s website at https://investor.precisionbiosciences.com.

    The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d)

    Exhibits

     

    Exhibit
    No.

     

    Description

    99.1

    Press release of Precision BioSciences, Inc. dated May 15, 2025.

    104


    Cover Page Interactive Data File (embedded within the Inline XBRL document).


     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    PRECISION BIOSCIENCES, INC.

     

     

     

     

    Date:

    May 15, 2025

    By:

    /s/ John Alexander Kelly

     

     

     

    John Alexander Kelly

    Chief Financial Officer

     


    Get the next $DTIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DTIL

    DatePrice TargetRatingAnalyst
    1/10/2025$34.00Market Perform → Outperform
    BMO Capital Markets
    4/30/2024$19.00Buy
    Guggenheim
    6/17/2022$7.00Outperform
    BMO Capital Markets
    6/9/2022Outperform → Mkt Perform
    William Blair
    9/10/2021$23.00 → $26.00Buy
    Stifel
    More analyst ratings

    $DTIL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

      - PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 - - Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time - - Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 - - Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing i

      5/14/25 4:30:00 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

      Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may ena

      5/8/25 7:01:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

      Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will present initial safety data from the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV program for the treatment of chronic hepatitis B during a late breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress being held May 7-10, 2025, in Amsterdam, Netherlands. "We are pleased to share initial safety data from the ELIMINATE-B trial for PBGENE-HBV at this year's EASL congress. Since initiating the trial, we have made rap

      5/7/25 7:01:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DTIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Precision BioSciences upgraded by BMO Capital Markets with a new price target

      BMO Capital Markets upgraded Precision BioSciences from Market Perform to Outperform and set a new price target of $34.00

      1/10/25 7:46:05 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Precision BioSciences with a new price target

      Guggenheim initiated coverage of Precision BioSciences with a rating of Buy and set a new price target of $19.00

      4/30/24 6:25:20 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Precision BioSciences with a new price target

      BMO Capital Markets initiated coverage of Precision BioSciences with a rating of Outperform and set a new price target of $7.00

      6/17/22 7:26:31 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DTIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Buehler Kevin bought $21,122 worth of shares (4,523 units at $4.67), increasing direct ownership by 52% to 13,235 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/28/25 7:02:15 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Brown Melinda bought $8,735 worth of shares (1,839 units at $4.75), increasing direct ownership by 25% to 9,057 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/28/25 7:00:04 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Germano Geno J bought $17,225 worth of shares (3,250 units at $5.30), increasing direct ownership by 42% to 11,057 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/27/25 7:00:04 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DTIL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Buehler Kevin bought $21,122 worth of shares (4,523 units at $4.67), increasing direct ownership by 52% to 13,235 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/28/25 7:02:15 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Brown Melinda bought $8,735 worth of shares (1,839 units at $4.75), increasing direct ownership by 25% to 9,057 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/28/25 7:00:04 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Germano Geno J bought $17,225 worth of shares (3,250 units at $5.30), increasing direct ownership by 42% to 11,057 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/27/25 7:00:04 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DTIL
    Leadership Updates

    Live Leadership Updates

    See more
    • Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

      - Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple in vivo gene editing programs; Expected cash runway into the second half of 2026 - Regained control of three advanced preclinical programs for development internally or with partners, including a novel gene editing approach for Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDA

      8/1/24 7:15:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

      Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural member of Precision's Hepatitis SAB, to provide counsel and deepen the Company's scientific and clinical expertise ahead of Precision's anticipated Investigational New Drug (IND) and/or Clinical Trial Application (CTA) submission of PBGE

      6/20/24 7:00:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences Appoints Melinda Brown to Board of Directors

      New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company's Board of Directors and Chair of the Board's Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202

      5/31/22 8:00:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DTIL
    Financials

    Live finance-specific insights

    See more
    • Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

      - PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 - - Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time - - Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 - - Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing i

      5/14/25 4:30:00 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

      Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may ena

      5/8/25 7:01:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

      Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key

      3/21/25 7:01:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DTIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

      SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

      11/14/24 4:50:29 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

      SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

      11/14/24 4:00:06 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

      SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

      11/14/24 1:34:42 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DTIL
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Precision BioSciences Inc.

      SCHEDULE 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

      5/15/25 4:15:23 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)

      5/15/25 8:00:20 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Precision BioSciences Inc.

      10-Q - PRECISION BIOSCIENCES INC (0001357874) (Filer)

      5/15/25 7:34:23 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care